

R&D Cost of HSC Expansion Platform Technology for Cell and Gene Therapy Companies(Celaid Therapeutics Inc.)



City	Year of Establishment	Founder
Bunkyo-ku, Tokyo	2020	Nobuyuki Arakawa

Partner VC	Latest round of Fundraising	Valuation
Osaka University Venture Capital Co., Ltd.	Series B	Non-Disclosure

Contact Information :

e-mail : contact@celaidtx.com

Website : <https://celaidtx.com/en/>

○ Business Plan

To establish an effective and efficient culture and manufacturing platform for human hematopoietic stem cells — a critical bottleneck in the commercial production of gene-modified hematopoietic stem cell therapies and iPSC-derived T/NK cell products — thereby building the foundation for future technology licensing activities to biotech start-ups and global pharmaceutical companies.

○ Research Outline

This R&D project aims to out-license the platform technology to global customers — including multinational pharmaceutical companies, biotechnology firms, and CDMOs — by achieving the following objectives:

- ① Realization of 3D culture for hematopoietic stem cells
- ② Establishment of methods for generating and expanding high-quality iPSC-derived hematopoietic stem/progenitor cells
- ③ Acquisition of R&D data tailored to customer needs

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	PCA 2025~2027FY	JPY 399 million	Japan, United States, Europe etc.